Argus Research maintains Herbalife at Buy, raises price target to $20 from $15

Argus Research kept its Buy rating on Herbalife and increased its price target to $20 from $15, suggesting a 28.3% upside from the Nov 10 close of $15.59.

Original reporting
Published Nov 11, 2026, 2:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 2:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Argus Research maintains Herbalife at Buy, raises price target to $20 from $15 — source image
Decision brief

The 30-second read

$HLFBullishLow
01

Why it matters

A higher price target can influence short-term positioning, but without new disclosures it is unlikely to drive a sustained repricing.

02

Market read

This is a single-name bullish analyst update with a stated upside implication versus the Nov 10 close.

03

What to watch

Traders may discount PT changes if they are not accompanied by new earnings estimates, margin outlook revisions, or fresh guidance.

Relevance 4/10Novelty 4/10Timing: as of the analyst note publication date, before the next earnings or guidance catalyst

Background

The piece is an analyst note update from Argus Research on Herbalife.

Company-level read

Ticker impact

$HLFBullishMedium confidence
Context

Argus maintained Herbalife at Buy and raised its price target to $20 from $15, implying upside versus the Nov 10 close.

Expected impact

Likely mild upward bias as traders price in the higher analyst target, with follow-through depending on broader earnings/guidance expectations.

Evidence & confidence

The article provides only an analyst rating and price-target change, with no new company-specific operational or financial disclosure.

Market effects

Minimal, since this is a single-name analyst target change with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The raised target may reflect valuation assumptions rather than new fundamentals, so price may not follow if upcoming company results disappoint.

Key entities

  • Herbalife

    Subject of the analyst action: maintained Buy and raised price target to $20 from $15.

Related articles

$HLFMedAI 8/10

Herbalife Ltd (HLF) (Q3 2026) Earnings Call Highlights: Fifth Straight Quarter

Herbalife (HLF) reported Q3 2026 net sales of $1.4B, up 6% YoY, and adjusted EBITDA of $182M, beating guidance. Growth was driven by India and nutrition clubs, while EMEA and China saw declines. The company raised full-year sales guidance but expects gradual margin expansion. Interim CEO John DeSimone discussed product repositioning and new technology platforms. Operating cash flow rose 27% YoY, and net leverage improved to 2.0x.

$HLFHighAI 8/10

Why Herbalife Stock Is Up Today

Herbalife (HLF) shares rose 8% after Q3 results showed 6% revenue growth to $1.35B, with Asia Pacific up 18%. Adjusted net income increased 33% to $68.5M. The company raised full-year sales guidance and announced a $250M stock buyback program. According to interim CEO John DeSimone, growth is driven by 3M+ independent distributors.

$HLFMedAI 8/10

Herbalife Reports Q3 2026 Financial Results

Herbalife Ltd. reported Q3 2026 net sales of $1.35B, up 6% YoY, with regional growth varying. Adjusted EBITDA was $182.4M, EPS $0.55. Gross margin slightly declined to 77.3%. The company cited refinancing benefits and debt reduction. Management expects continued net sales growth.

$HLFHighAI 8/10

Herbalife (HLF) Q3 2026 Earnings Call Transcript

Herbalife (HLF) reported Q3 2026 net sales of $1.4B, up 6% YoY, and adjusted EBITDA of $182M, exceeding guidance. Interim CEO John DeSimone highlighted growth opportunities, including strengthening Nutrition Clubs and expanding the Bioniq brand. The company aims to enhance distributor support and technology capabilities.

$HLFMedAI 8/10

What Herbalife (HLF) Said on Its Q3 Earnings Call

Herbalife (HLF) reported Q3 sales growth of 5.1% in constant currency and 9% reported, with North America up 1.7%. FX reduced net sales by $21M. The company outlined priorities: nutrition clubs, tech platforms, and Bioniq brand growth. It expects Q4 sales growth of 0.5% to 4.5% and raised full-year sales guidance to 4.9% to 5.9%. Operating cash flow rose 27% YoY to $298M.